CGIX Cancer Genetics, Inc. gains 32% Dec 5, 2019

Cancer Genetics, Inc. develops, commercializes, and provides molecular and biomarker-based tests and services in the United States, India, and China. Its tests enable physicians to personalize the clinical management of each individual patient by providing genomic information to diagnose, monitor, and inform cancer treatment; and enable biotech and pharmaceutical companies involved in oncology trials to select candidate populations and reduce adverse drug reactions by providing information regarding genomic factors influencing subject responses to therapeutics. The company's clinical services provide information on diagnosis, prognosis, and predicting treatment outcomes of cancers to guide patient management. Its biopharma services offer companies with customized solutions for patient stratification and treatment selection through a suite of molecular- and biomarker-based testing services, customized assay development, and trial design consultation. The company's discovery services provide the tools and testing methods for companies and researchers to identify new molecular-based biomarkers for disease. It serves hospitals, cancer centers, clinics, academic institutions, and government-sponsored research institutions, as well as pharmaceutical and biotech companies performing clinical trials. The company collaborates with oncology centers and community-based hospitals to develop its proprietary diagnostic tests. Cancer Genetics, Inc. was founded in 1999 and is based in Rutherford, New Jersey.http://www.priceseries.com/trade/CGIX-Cancer-Genetics-Inc-stock-gains-32-percent-a-Trade-Record-by-priceSeries-2019112120191205.html

AQXP Aquinox Pharmaceuticals, Inc. gains 16% Aug 9, 2019

Aquinox Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, engages in discovering and developing targeted therapeutics in disease areas of inflammation and immuno-oncology. The company primarily focuses on anti-inflammatory product candidates targeting SH2-containing inositol-5'-phosphatase 1 (SHIP1) enzyme, a key regulator of a cellular signaling pathway in immune cells. Its lead product candidate is AQX-1125, a small molecule activator of SHIP1 that is in Phase III clinical trials for treatment in interstitial cystitis/bladder pain syndrome, a chronic inflammatory disease of the bladder. The company was founded in 2003 and is headquartered in Vancouver, Canada.http://www.priceseries.com/trade/AQXP-Aquinox-Pharmaceuticals-Inc-stock-gains-16-percent-a-Trade-Record-by-priceSeries-2019111820190809.html

YNDX Yandex N.V. gains 17% Dec 4, 2019

Yandex N.V. operates an Internet search engine in the Russian Federation and internationally. The company offers search, location-based, personalized, and mobile services that enable users to find information, and communicate and connect over the Internet from desktops and mobile devices. It provides maps and location-based services, such as Yandex.Maps, Yandex.Navigator, and Yandex.Transport; Yandex.Mail that provides users access to their email accounts; Yandex.Disk, a cloud-based storage service; Yandex.News, an online news aggregation service; Yandex.Weather, a service that offers hyperlocal weather information; and Yandex Browser for desktops and mobile platforms. The company also provides Yandex.Direct, an auction-based advertising placement platform; Yandex Ad Network service; Yandex RTB, a programmatic advertising product; mobile advertising products; Yandex.Spravochnik, a business directory; and Yandex.Market, an e-commerce gateway service. In addition, it offers Yandex.Taxi, an on-demand transportation service; Auto.ru, a classified platform for used and new cars, other private and commercial vehicles, and spare parts; Yandex.Realty, a real estate classifieds service; Yandex.Jobs, a job search Website; and Yandex.Travel, a service that allow users to search for a vacation. Further, it offers KinoPoisk, a Russian language Website for movies, TV series, and celebrity content; Yandex.Music, a music streaming service; Yandex.Afisha platform that allow users to buy tickets to cinemas, theaters, and concerts online; and Yandex.TV Program, a service providing users with an up to date schedule of broadcast, cable and digital TV channels, as well as an option to view certain TV channels online. Additionally, it offers Yandex Zen, which scours the Web for content; and Yandex Launcher that allows users to grouping applications on their smartphone into various categories. Yandex N.V. was incorporated in 2004 and is headquartered in Moscow, the Russian Federation.http://www.priceseries.com/trade/YNDX-Yandex-NV-stock-gains-17-percent-a-Trade-Record-by-priceSeries-2019111420191204.html

VTNR Vertex Energy, Inc gains 34% Dec 4, 2019

Vertex Energy, Inc., an environmental services company, provides a range of services designed to aggregate, process, and recycle industrial and commercial waste systems in 13 states, primarily in the Gulf Coast and Central Midwest Region of the United States. It operates in three divisions: Black Oil, Refining and Marketing, and Recovery. The Black Oil division collects and purchases used motor oil directly from third-party generators; aggregates used motor oil from a network of local and regional collectors; and sells used motor oil to customers for use as a feedstock or replacement fuel for industrial burners. The Refining and Marketing division gathers hydrocarbon streams in the form of petroleum distillates, transmix, and other chemical products that are purchased from pipeline operators, refineries, chemical processing facilities, and third-party providers; and sells end products, such as gasoline blendstock, pygas, and fuel oil cutter stock to oil companies or to petroleum trading and blending companies. The Recovery division generates solutions for the recovery and management of hydrocarbon streams; and provides dismantling, demolition, decommission, and marine salvage services, as well as owns and operates a fleet of trucks and other vehicles used for shipping and handling equipment and scrap materials. Vertex Energy, Inc. is headquartered in Houston, Texas.http://www.priceseries.com/trade/VTNR-Vertex-Energy-Inc-stock-gains-34-percent-a-Trade-Record-by-priceSeries-2019110820191204.html

VRTU Virtusa Corp. gains 18% Dec 4, 2019

Virtusa Corporation operates as an information technology (IT) services company. It offers business and IT consulting services comprising application inventory and portfolio assessment, business/technology alignment analysis, business process optimization, and quality assurance process consulting; accelerated solution design, enterprise architecture analysis, technology roadmaps, product evaluation and selection, and business process analysis and design; and program governance and change management, program management planning, and complex program management. The company also provides technology implementation services, such as application development, package implementation and integration, software product engineering, application maintenance and support, business process management, CRM and SAP implementation, customer experience and content management, enterprise mobility, cloud computing, and social media solutions; systems consolidation and rationalization, technology migration and porting, and legacy application Web-enablement; data management, business intelligence, reporting and decision support, master data management, data integration, and big data analytics; and software quality assurance and managed testing services. In addition, it offers application outsourcing services, such as the production support, application maintenance and enhancement, and ongoing software engineering; systems and database administration, and monitoring; outsourcing of quality assurance planning; and preparation and execution of test cases, scripts, and data. Virtusa Corporation provides its services to communications and technology; banking, financial services, and insurance; and media and information industries worldwide. The company was formerly known as eRunway, Inc. and changed its name to Virtusa Corporation in April 2002. Virtusa Corporation was founded in 1996 and is headquartered in Westborough, Massachusetts.http://www.priceseries.com/trade/VRTU-Virtusa-Corp-stock-gains-18-percent-a-Trade-Record-by-priceSeries-2019103120191204.html

PLNT Planet Fitness, Inc. gains 16% Dec 4, 2019

Planet Fitness, Inc., through its subsidiaries, franchises and operates fitness centers. It operates through three segments: Franchise, Corporate-Owned Stores, and Equipment. The Franchise segment is involved in franchising business in the United States, Puerto Rico, Canada, and the Dominican Republic. The Corporate-Owned Stores segment operates corporate-owned stores in the United States and Canada. The Equipment segment engages sells fitness equipment to franchisee-owned stores. As of December 31, 2016, the company had 1,313 owned and franchised locations in 48 states, the District of Columbia, Puerto Rico, the Dominican Republic, and Canada. Planet Fitness, Inc. was founded in 1992 and is headquartered in Newington, New Hampshire.http://www.priceseries.com/trade/PLNT-Planet-Fitness-Inc-stock-gains-16-percent-a-Trade-Record-by-priceSeries-2019110720191204.html

COLL Collegium Pharmaceutical, Inc. gains 60% Dec 4, 2019

Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, develops and commercializes abuse-deterrent products that incorporate its DETERx platform technology for the treatment of chronic pain and other diseases. It offers Xtampza, an oral formulation of oxycodone, for the management of pain. The company also develops Onsolis, a transmucosal immediate-release fentanyl film indicated for the management of breakthrough pain in cancer patients 18 years of age and older. The company is also developing COL-195, a hydrocodone for the treatment of chronic pain; COL-172, an oxymorphone for the treatment of chronic pain; COL-196, a morphine formulation to treat pain; and COL-171, a methylphenidate formulation for the treatment of attention deficit hyperactivity disorder. The company was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. Collegium Pharmaceutical, Inc. was incorporated in 2002 and is headquartered in Canton, Massachusetts.http://www.priceseries.com/trade/COLL-Collegium-Pharmaceutical-Inc-stock-gains-60-percent-a-Trade-Record-by-priceSeries-2019110120191204.html

ARDX Ardelyx, Inc. gains 21% Dec 4, 2019

Ardelyx, Inc. develops and sells therapeutics for the treatment of cardio renal and gastrointestinal diseases in the United States. Its lead product candidate is tenapanor, which is in Phase III clinical trial for the treatment of patients with irritable bowel syndrome with constipation, as well as in Phase III clinical trial for the treatment of hyperphosphatemia in end-stage renal disease patients on dialysis. The company is also developing RDX7675, which is in Phase III clinical trial for the treatment of people with hyperkalemia; and RDX8940 in Phase I clinical trial for the treatment of patients with NASH and other gastrointestinal indications. Its drug candidates in the stages of research and development include RDX013 for the treatment of patients with hyperkalemia; RDX011 for the discovery and development of second-generation NHE3 inhibitors; and RDX023 for the discovery and development of gut-biased FXR agonists for the treatment of GI and inflammatory diseases. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was founded in 2007 and is headquartered in Fremont, California.http://www.priceseries.com/trade/ARDX-Ardelyx-Inc-stock-gains-21-percent-a-Trade-Record-by-priceSeries-2019110720191204.html

AQXP Aquinox Pharmaceuticals, Inc. gains 16% Aug 9, 2019

Aquinox Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, engages in discovering and developing targeted therapeutics in disease areas of inflammation and immuno-oncology. The company primarily focuses on anti-inflammatory product candidates targeting SH2-containing inositol-5'-phosphatase 1 (SHIP1) enzyme, a key regulator of a cellular signaling pathway in immune cells. Its lead product candidate is AQX-1125, a small molecule activator of SHIP1 that is in Phase III clinical trials for treatment in interstitial cystitis/bladder pain syndrome, a chronic inflammatory disease of the bladder. The company was founded in 2003 and is headquartered in Vancouver, Canada.http://www.priceseries.com/trade/AQXP-Aquinox-Pharmaceuticals-Inc-stock-gains-16-percent-a-Trade-Record-by-priceSeries-2019111820190809.html

ABEO Abeona Therapeutics Inc. gains 17% Dec 4, 2019

Abeona Therapeutics Inc., a biopharmaceutical company, focuses on developing and delivering gene therapy and plasma-based products for severe and life-threatening rare diseases. The company offers MuGard, a mucoadhesive oral wound rinse for mucositis, stomatitis, aphthous ulcers, and traumatic ulcers; and ProctiGard, a mucoadhesive oral wound rinse for the treatment of rectal mucositis and radiation proctitis. Its lead program is an adeno-associated virus (AAV)-based gene therapy for sanfilippo syndrome. The company develops ABO-101 for Mucopolysaccharidosis (MPS) III, a sanfilippo syndrome Type B; ABO-102 for MPS III, a sanfilippo syndrome Type A; ABO-201 for juvenile batten disease; ABO-301 for fanconi anemia; and clustered, regularly interspaced short palindromic repeats (CRISPR)-CRISPR associated protein 9 AAV for rare blood diseases. It also develops PTB-101 salt diafiltration process (SDF) Alpha, a alpha1-proteinase inhibitor for chronic augmentation and maintenance therapy in adults with clinically evident emphysema due to severe deficiency of alpha1-proteinase inhibitor; and PTB-102 SDF IVIG, an intravenous immunoglobulin for autoimmune, infectious, and idiopathic diseases. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. was incorporated in 1989 and is based in Dallas, Texas.http://www.priceseries.com/trade/ABEO-Abeona-Therapeutics-Inc-stock-gains-17-percent-a-Trade-Record-by-priceSeries-2019112220191204.html